Venus Medtech (Hangzhou) Inc. ("Venus Medtech"), is the leader in transcatheter structural heart valvular therapies in China. The company is committed to the development and commercialization of innovative medical devices in the field of structural heart disease. In 2022, following the acquisition of an Israeli company specializing in Cardiovascular Replacement Devices for Minimally Invasive Surgery, the Venus Global Heart Valve Innovation Center was established in Israel. This move is part of a strategy to enhance the company's global innovation framework and product offerings, capitalizing on Israel's expertise and innovative culture in the medical device sector.